VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 295 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2018. The put-call ratio across all filers is 2.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $882,000 | -18.7% | 37,966 | -44.3% | 0.00% | -33.3% |
| Q1 2018 | $1,085,000 | +122.8% | 68,140 | +190.8% | 0.00% | +200.0% |
| Q4 2017 | $487,000 | -96.3% | 23,434 | -81.8% | 0.00% | -97.9% |
| Q4 2015 | $13,097,000 | -50.4% | 128,845 | -13.0% | 0.05% | -52.5% |
| Q3 2015 | $26,419,000 | -32.9% | 148,106 | -16.4% | 0.10% | -28.3% |
| Q2 2015 | $39,351,000 | +17.9% | 177,136 | +5.4% | 0.14% | +17.9% |
| Q1 2015 | $33,383,000 | -28.4% | 168,073 | -48.4% | 0.12% | -28.7% |
| Q4 2014 | $46,631,000 | +9.4% | 325,840 | +0.3% | 0.16% | +6.5% |
| Q3 2014 | $42,638,000 | +7.4% | 324,985 | +3.2% | 0.15% | +5.5% |
| Q2 2014 | $39,706,000 | -0.9% | 314,825 | +3.5% | 0.15% | -6.4% |
| Q1 2014 | $40,086,000 | +17.0% | 304,070 | +4.2% | 0.16% | +14.7% |
| Q4 2013 | $34,273,000 | +4.5% | 291,930 | -7.1% | 0.14% | -2.9% |
| Q3 2013 | $32,800,000 | +25.8% | 314,390 | +3.8% | 0.14% | +15.7% |
| Q2 2013 | $26,079,000 | – | 302,960 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |